SEC Form 10-Q filed by FitLife Brands Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT |
For the transition period from N/A to N/A
Commission File No.
|
|
|
(Exact name of registrant as specified in its charter) |
|
|
|
|
|
(State or other jurisdiction of incorporation) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(
(Issuer’s telephone number)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
The |
Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
|
☒ |
Small reporting company |
|
|
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
As of August 13, 2024, a total of
FITLIFE BRANDS, INC.
INDEX TO FORM 10-Q FILING
FOR THE QUARTER ENDED JUNE 30, 2024
TABLE OF CONTENTS
|
PAGE |
||
|
PART I - FINANCIAL INFORMATION |
||
|
Item 1. |
Financial Statements |
|
|
Condensed Consolidated Balance Sheets (unaudited) |
1 | |
|
Condensed Consolidated Statements of Income and Comprehensive Income (unaudited) |
2 | |
|
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) |
3 | |
|
Condensed Consolidated Statements of Cash Flows (unaudited) |
4 | |
|
Notes to Condensed Consolidated Financial Statements (unaudited) |
5 | |
|
Item 2. |
Management’s Discussion & Analysis of Financial Condition and Results of Operations |
15 |
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
25 |
|
Item 4. |
Controls and Procedures |
26 |
|
PART II - OTHER INFORMATION |
||
|
Item 1. |
Legal Proceedings |
27 |
|
Item 1A. |
Risk Factors |
27 |
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
27 |
|
Item 3. |
Defaults Upon Senior Securities |
27 |
|
Item 5. |
Other Information |
27 |
|
Item 6. |
Exhibits |
27 |
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (“Quarterly Report”), including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this Quarterly Report, includes forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “proposed”, “intended”, or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. There may be events in the future that we are not able to accurately predict or control. Before you invest in our securities, you should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline and you could lose all or part of your investment. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.
PART I
FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
|
June 30, 2024 |
December 31, 2023 |
|||||||
|
(Unaudited) |
||||||||
|
ASSETS: |
||||||||
|
CURRENT ASSETS |
||||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Restricted cash |
||||||||
|
Accounts receivable, net of allowance of doubtful accounts of $ |
||||||||
|
Inventories, net of allowance for obsolescence of $ |
||||||||
|
Sales tax receivable |
||||||||
|
Prepaid expense and other current assets |
||||||||
|
Total current assets |
||||||||
|
Property and equipment, net |
||||||||
|
Right of use asset |
||||||||
|
Intangibles, net of amortization of $ |
||||||||
|
Goodwill |
||||||||
|
Deferred tax asset |
||||||||
|
TOTAL ASSETS |
$ | $ | ||||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY: |
||||||||
|
CURRENT LIABILITIES: |
||||||||
|
Accounts payable |
$ | $ | ||||||
|
Accrued expense and other liabilities |
||||||||
|
Income taxes payable |
||||||||
|
Product returns |
||||||||
|
Term loan – current portion |
||||||||
|
Lease liability - current portion |
||||||||
|
Total current liabilities |
||||||||
|
Term loan, net of current portion and unamortized deferred finance costs |
||||||||
|
Long-term lease liability, net of current portion |
||||||||
|
Deferred tax liability |
||||||||
|
TOTAL LIABILITIES |
||||||||
|
STOCKHOLDERS’ EQUITY: |
||||||||
| Preferred stock, $ |
||||||||
|
Common stock, $ |
||||||||
|
Additional paid-in capital |
||||||||
|
Retained earnings (accumulated deficit) |
( |
) | ||||||
|
Foreign currency translation adjustment |
( |
) | ( |
) | ||||
|
TOTAL STOCKHOLDERS' EQUITY |
||||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands, except per share data)
(Unaudited)
|
Three months ended June 30 |
Six months ended June 30 |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
Revenue |
$ | $ | $ | $ | ||||||||||||
|
Cost of goods sold |
||||||||||||||||
|
Gross profit |
||||||||||||||||
|
OPERATING EXPENSE: |
||||||||||||||||
|
Advertising and marketing |
||||||||||||||||
|
Selling, general and administrative |
||||||||||||||||
|
Merger and acquisition related |
||||||||||||||||
|
Depreciation and amortization |
||||||||||||||||
|
Total operating expense |
||||||||||||||||
|
OPERATING INCOME |
||||||||||||||||
|
OTHER EXPENSE (INCOME) |
||||||||||||||||
|
Interest income |
( |
) |
( |
) |
( |
) | ( |
) | ||||||||
|
Interest expense |
||||||||||||||||
|
Foreign exchange (gain) loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Total other expense (income) |
( |
) | ||||||||||||||
|
INCOME BEFORE INCOME TAX PROVISION |
||||||||||||||||
|
PROVISION FOR INCOME TAXES |
||||||||||||||||
|
NET INCOME |
$ | $ | $ | $ | ||||||||||||
|
NET INCOME PER SHARE |
||||||||||||||||
|
Basic |
$ | $ | $ | $ | ||||||||||||
|
Diluted |
$ | $ | $ | $ | ||||||||||||
|
Basic weighted average common shares |
||||||||||||||||
|
Diluted weighted average common shares |
||||||||||||||||
|
COMPREHENSIVE INCOME: |
||||||||||||||||
|
NET INCOME |
$ | $ | $ | $ | ||||||||||||
|
Foreign currency translation adjustment |
( |
) | ( |
) | ||||||||||||
|
Comprehensive income |
$ | $ | $ | $ | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands)
(Unaudited)
| Common Stock | Additional paid-in |
Retained earnings (accumulated | Foreign currency translation |
|||||||||||||||||||||
|
Shares |
Amount |
capital |
deficit) |
adjustment |
Total |
|||||||||||||||||||
|
THREE MONTHS ENDED JUNE 30, 2024 |
||||||||||||||||||||||||
|
APRIL 1, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Comprehensive income |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Net income |
- | |||||||||||||||||||||||
|
JUNE 30, 2024 |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||
|
SIX MONTHS ENDED JUNE 30, 2024 |
||||||||||||||||||||||||
|
JANUARY 1, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Comprehensive income |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Net income |
- | |||||||||||||||||||||||
|
JUNE 30, 2024 |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||
|
THREE MONTHS ENDED JUNE 30, 2023 |
||||||||||||||||||||||||
|
APRIL 1, 2023 |
$ | $ | $ | ( |
) | $ | $ | |||||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Comprehensive income |
- | |||||||||||||||||||||||
|
Net income |
- | |||||||||||||||||||||||
|
JUNE 30, 2023 |
$ | $ | $ | ( |
) | $ | $ | |||||||||||||||||
|
SIX MONTHS ENDED JUNE 30, 2023 |
||||||||||||||||||||||||
|
JANUARY 1, 2023 |
$ | $ | $ | ( |
) | $ | $ | |||||||||||||||||
|
Shares surrendered by former employee |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Comprehensive income |
- | |||||||||||||||||||||||
|
Net income |
- | |||||||||||||||||||||||
|
JUNE 30, 2023 |
$ | $ | $ | ( |
) | $ | $ | |||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands)
(Unaudited)
|
Six months ended June 30, |
||||||||
|
2024 |
2023 |
|||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
|
Net income |
$ | $ | ||||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation and amortization |
||||||||
|
Allowance for doubtful accounts |
( |
) | ||||||
|
Allowance for inventory obsolescence |
( |
) | ||||||
|
Stock-based compensation |
||||||||
|
Amortization of deferred financing costs |
||||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable - trade |
( |
) |
( |
) |
||||
|
Inventories |
( |
) | ||||||
|
Deferred tax asset |
||||||||
|
Prepaid expense, other current assets and sales tax receivable |
( |
) | ||||||
|
Right-of-use asset |
||||||||
|
Accounts payable |
( |
) | ||||||
|
Lease liability |
( |
) |
( |
) |
||||
|
Accrued expense, other liabilities and income taxes payable |
||||||||
|
Product returns |
( |
) | ||||||
|
Net cash provided by operating activities |
||||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
|
Purchase of property and equipment |
( |
) |
( |
) | ||||
|
Cash paid for acquisition of Mimi’s Rock Corp. |
( |
) | ||||||
|
Net cash used in investing activities |
( |
) |
( |
) | ||||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
|
Payments on term loans |
( |
) | ( |
) | ||||
|
Proceeds from term loans |
||||||||
|
Net cash provided by (used in) financing activities |
( |
) | ||||||
|
Foreign currency impact on cash |
( |
) | ||||||
|
CHANGE IN CASH AND RESTRICTED CASH |
( |
) | ||||||
|
CASH AND RESTRICTED CASH, BEGINNING OF PERIOD |
||||||||
|
CASH AND RESTRICTED CASH, END OF PERIOD |
$ | $ | ||||||
|
Supplemental cash flow disclosure |
||||||||
|
Cash paid for income taxes |
$ | $ | ||||||
|
Cash paid for interest, net of amounts capitalized |
$ | $ |
The accompanying notes are an integral part of these condensed consolidated financial statements.
FITLIFE BRANDS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands, except per share data)
(Unaudited)
NOTE 1 - DESCRIPTION OF BUSINESS
Summary
FitLife Brands, Inc. (the “Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products"); and (iv) MusclePharm.
The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through approximately
FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $
NOTE 2 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three- and six-month periods ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2024.
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company prepares its financial statements in accordance with accounting principles generally accepted in the U.S. (“GAAP”). Significant accounting policies are as follows:
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements.
Foreign Currency Translation
The functional currency of the Company is the U.S. dollar (“USD”). The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar (“CAD”). The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying condensed consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.
Use of Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.
Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.
Revenue Recognition
The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.
The Company accounts for revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer.
All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.
The Company’s products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in advertising expense in the condensed consolidated statements of income and comprehensive income.
The Company disaggregates revenue into geographical regions and distribution channels. The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.
Online revenue during the three months ended June 30, 2024 and 2023 was approximately
Sales to customers in the U.S. were approximately
Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.
For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration (“FDA”).
A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.
Customer and Vendor Concentration
Net sales to GNC during the three-month periods ended June 30, 2024 and 2023 represent
As of June 30, 2024 and December 31, 2023, there was vendor who accounted for more than
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. The Company has approximately $
Leases
We lease certain corporate office space and office equipment under lease agreements with monthly payments over a period of
Goodwill
The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.
As the Company uses the market approach to determine fair value of the reporting unit, the price of its Common Stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.
Management determined there were no indicators of impairment at June 30, 2024 or December 31, 2023. The Company will perform its next impairment analysis in December 2024.
Intangible Assets
The Company has certain intangible assets that were recorded at their fair value at the time of acquisition. The finite-lived intangible assets consist of client relationships, formulations, and website. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful life. Intangible assets with indefinite lives, which consist of brands and trademarks, are not amortized but are tested for impairment annually or when indicators of impairment exist. Factors that management considers in this assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy, and changes in the composition and carrying amounts of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than it’s carrying value, a quantitative assessment is then performed. The Company noted no indicators of impairment for intangible assets as of June 30, 2024, and December 31, 2023.
Acquisitions and Business Combinations
The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.
Income Taxes
Provision for income taxes consists of current and deferred tax expense. Current tax expense is the expected tax payable on the taxable income for the year using tax rates enacted in the countries where the Company and its subsidiaries operate and generate taxable income. The Company accounts for income taxes using the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets may also result from unused losses and other deductions carried forward. An assessment of the probability that a deferred tax asset will be recovered is made prior to any deferred tax asset being recognized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized, or that future deductibility is uncertain.
The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates. The effective income tax rate was
Net Income Per Share
Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase Common Stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the Common Stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an antidilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.
|
Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
Net income available to common shareholders |
$ | $ | $ | $ | ||||||||||||
|
Weighted average common shares - basic |
||||||||||||||||
|
Dilutive effect of outstanding warrants and stock options |
||||||||||||||||
|
Weighted average common shares - diluted |
||||||||||||||||
|
Net income per common share: |
||||||||||||||||
|
Basic |
$ | $ | $ | $ | ||||||||||||
|
Diluted |
$ | $ | $ | $ | ||||||||||||
Fair Value Measurements
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:
|
● |
Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. |
|
|
● |
Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
|
|
● |
Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company’s own data. |
The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of our notes payable approximate their fair value based on the market interest rates of these notes.
Segment
The Company operates in one segment, providing nutritional supplements and wellness products to health-conscious consumers. The Company’s chief operating decision maker is the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.
Reclassifications
Certain reclassifications have been made in the Company’s financial statements. Advertising and marketing expense for the three and six months ended June 30, 2023 were previously reported as part of selling, general and administrative expense. Advertising and marketing expense is now segregated and reported separately in the accompanying statement of income and comprehensive income to conform to current period presentation. These reclassifications had no impact on earnings or stockholders’ equity.
Recently Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure (“ASC 280”), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, including the significant segment expense disclosures. This standard will be effective for the Company on January 1, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted. The updates required by this standard should be applied retrospectively to all periods presented in the financial statements. The adoption of this standard did not have a material impact on its results of operations, financial position or cash flows.
Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
NOTE 4 – INVENTORIES
The Company’s inventory is carried at the lower of cost or net realizable value using the first-in, first-out (“FIFO”) method. The Company evaluates the need to record adjustments for inventory on a regular basis. Company policy is to evaluate all inventories including components and finished goods for all of its product offerings across all of the Company’s operating subsidiaries.
The Company recognizes an allowance for obsolescence for expiring, excess, and slow-moving inventory. To calculate the allowance, the Company analyzes sales projections for each stock-keeping unit (“SKU”) relative to the remaining shelf life of the product. The value of any finished goods inventory projected to expire prior to sale is included in the allowance.
The total allowance for expiring, excess and slow-moving inventory items as of June 30, 2024 and December 31, 2023 amounted to $
|
June 30, 2024 |
December 31, 2023 |
|||||||
|
(Unaudited) |
||||||||
|
Finished goods |
$ | $ | ||||||
|
Components |
||||||||
|
Allowance for obsolescence |
( |
) |
( |
) |
||||
|
Total |
$ | $ | ||||||
NOTE 5 - PROPERTY AND EQUIPMENT
The Company had property and equipment as of June 30, 2024 and December 31, 2023 as follows:
|
June 30, 2024 |
December 31, 2023 |
|||||||
|
(Unaudited) |
||||||||
|
Equipment |
$ | $ | ||||||
|
Accumulated depreciation |
( |
) |
( |
) |
||||
|
Total |
$ | $ | ||||||
Depreciation expense for the three months ended June 30, 2024 and 2023 was $
NOTE 6 – NOTES PAYABLE
Notes payable consisted of the following:
|
June 30, 2024 |
December 31, 2023 |
|||||||
|
(Unaudited) |
||||||||
|
Term loans |
$ | $ | ||||||
|
Unamortized debt issuance costs |
( |
) | ( |
) | ||||
|
Total |
$ | $ | ||||||
|
Current |
( |
) | ( |
) | ||||
|
Long term |
$ | $ | ||||||
Credit Agreements – First Citizens Bank
On February 23, 2023, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with First Citizens Bank (the “Bank”), amending and restating that certain Credit Agreement, dated September 24, 2019, between the Company and the Bank. Pursuant to the Previous Credit Agreement, the Bank provided the Company with a term loan for the principal amount of $
Second Amended and Restated Credit Agreement
On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with the Bank, amending and restating the Credit Agreement between the Company and the Bank. Pursuant to the Amended Credit Agreement, the Bank provided the Company with an additional Term Loan (“Term Loan B”, and together with Term Loan A, the “Term Loans”) for the principal amount of $
Pursuant to the Amended Credit Agreement, the Term Loans accrue interest at a per annum rate equal to
The Amended Credit Agreement contains customary events of default (each an “Event of Default”), which upon the occurrence of an Event of Default, among other things, interest will accrue at the Applicable Rate plus
As of June 30, 2024, the borrowings outstanding on the Term Loans and Line of Credit were $
NOTE 7 - EQUITY
The Company is authorized to issue
Common Stock Issued for Services
In February 2021, the Company granted an officer an aggregate of
Share Repurchase Program
On March 17, 2023, the Board approved the extension of the Company’s previously authorized share repurchase program, initially approved by the Board on August 16, 2019, as amended on September 23, 2019, November 6, 2019 and February 1, 2021 (“Share Repurchase Program”). Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $
During the six months ended June 30, 2024 and 2023, the Company did repurchase any Common Stock under the 2023 Share Repurchase Program. As of June 30, 2024, the Company may purchase $
Options
Information regarding options outstanding as of June 30, 2024 is as follows:
|
Number of options |
Weighted average exercise price |
Weighted average remaining life (years) |
||||||||||
|
Outstanding, December 31, 2023 |
$ | |||||||||||
|
Issued |
- | |||||||||||
|
Exercised |
- | |||||||||||
|
Forfeited |
- | |||||||||||
|
Outstanding, June 30, 2024 |
$ | |||||||||||
|
Outstanding |
Exercisable |
||||||||||||||||||||||
|
Exercise price per share |
Total number of options |
Weighted average remaining life (years) |
Weighted average exercise price |
Number of vested options |
Weighted average exercise price |
||||||||||||||||||
| $ |
- | $ | $ | ||||||||||||||||||||
| $ |
- | $ | $ | ||||||||||||||||||||
|
$ |
$ |
||||||||||||||||||||||
The closing stock price for the Company’s stock on June 28, 2024 was $
During the three-month periods ended June 30, 2024 and 2023, the Company recognized stock-based compensation of $
NOTE 8 – ACQUISITION OF MIMI’S ROCK CORP
On February 28, 2023, the Company acquired all the equity interests of Mimi’s Rock Corp. ("MRC") for the purchase price of $
The Company accounted for the acquisition as a business combination under ASC 805, Business Combinations (“ASC 805”). As a result of the MRC acquisition, the Company recorded intangible assets – brands of $
The purchase was intended to augment and diversify the Company’s product offerings and lineup. Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business.
Pro Forma Condensed Combined Financial Information (Unaudited, in thousands)
The following presents the Company’s unaudited pro forma financial information for the three and six months ended June 30, 2023, giving effect to the acquisition of MRC as if it had occurred at January 1, 2023. Included in the pro forma information are adjustments to (1) remove non-recurring transaction-related costs related to the acquisition of MRC, (2) remove the interest costs from MRC’s debt prior to the closing of the acquisition, and (3) recognize interest expense based on the projected balance of the Term Loan A for the respective periods presented for this pro forma.
|
Six months ended |
||||
|
June 30, 2023 |
||||
|
Revenue |
$ | |||
|
Net income |
$ | |||
|
Diluted net income per share |
$ | |||
The pro forma adjustments do not reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does not purport to present what the Company’s results would actually have been had the transaction actually occurred on the dates presented or to project the combined company’s results of operations or financial position for any future period.
MRC revenue for the three months ended June 30, 2024 and 2023 was $
NOTE 9. ACQUISITION OF MUSCLEPHARM ASSETS
On October 10, 2023, the Company acquired substantially all of the assets and assumed none of the liabilities other than de minimus cure costs relating to certain assumed contracts of MusclePharm through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. Total consideration for the acquisition, including legal expense, amounted to $
The Company accounted for the transaction as an asset acquisition under ASC 805. The assets acquired consist of indefinite life intellectual property – brands with an estimated value of $
NOTE 10 – COMMITMENTS AND CONTINGENCIES
We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.
NOTE 11 – SUBSEQUENT EVENTS
On July 19, 2024, the Company amended and extended the existing lease agreement for its headquarters in Omaha, Nebraska. The amended lease agreement extends the lease term for an additional six years (
|
ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this "Quarterly Report"). This discussion and analysis may contain forward-looking statements based on assumptions about our future business. Unless otherwise stated, all dollar amounts are in thousands, except per share data.
Overview
FitLife Brands, Inc. (the “Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products"); and (iv) MusclePharm.
The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through approximately 16,000 retail locations, which include specialty, mass, and online. The Company distributes the MRC Products primarily online. MusclePharm’s products are sold to wholesale customers as well as online directly to the end consumer.
FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the Nasdaq Capital Market.
Recent Acquisitions
Acquisition of Mimi’s Rock Corp
On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire MRC. On February 28, 2023, the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was $17,099, of which $12,500 was funded using proceeds from a term loan provided by First Citizens Bank with the remainder funded from the Company’s available cash. See Note 8 to the financial statements for additional disclosure regarding the acquisition of MRC.
Acquisition of MusclePharm Assets
On October 10, 2023, the Company acquired substantially all of the assets of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed none of the liabilities of MusclePharm other than de minimus cure costs relating to certain assumed contracts. Total consideration for the acquisition was approximately $18,500. Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note 9 for additional disclosure regarding the acquisition of MusclePharm.
Results of Operations
Comparison of the three months ended June 30, 2024 to the three months ended June 30, 2023
|
Three months ended |
||||||||||||||||
|
June 30, 2024 |
June 30, 2023 |
Change ($) |
Change (%) |
|||||||||||||
|
(Unaudited) |
||||||||||||||||
|
Revenue |
$ | 16,930 | $ | 14,760 | $ | 2,170 | 15 | % | ||||||||
|
Cost of goods sold |
9,350 | 8,795 | 555 | 6 | % | |||||||||||
|
Gross profit |
7,580 | 5,965 | 1,615 | 27 | % | |||||||||||
|
Gross margin |
44.8 | % | 40.4 | % |
n/m |
4.4 | % | |||||||||
|
Advertising and marketing |
1,326 | 1,457 | (131 | ) | (9 | )% | ||||||||||
|
Selling. general and administrative (“SG&A”) |
2,528 | 1,786 | 742 | 42 | % | |||||||||||
|
Merger and acquisition related |
24 | 115 | (91 | ) | (79 | )% | ||||||||||
|
Depreciation and amortization |
27 | 23 | 4 | 17 | % | |||||||||||
|
Total operating expense |
3,905 | 3,381 | 524 | 15 | % | |||||||||||
|
Operating income |
3,675 | 2,584 | 1,091 | 42 | % | |||||||||||
|
Other expense (income), net |
318 | (15 | ) | 333 |
n/m |
% | ||||||||||
|
Provision for income tax |
729 | 635 | 94 | 15 | % | |||||||||||
|
Net income |
2,628 | $ | 1,964 | $ | 664 | 34 | % | |||||||||
Revenue. Revenue for the three months ended June 30, 2024 increased 15% to $16,930 as compared to $14,760 for the three months ended June 30, 2023. The increase in revenue for the three months ended June 30, 2024 compared to the prior period is primarily due to the acquisition of the MusclePharm assets, which were acquired on October 10, 2023, partially offset by a decline in legacy FitLife revenue.
Legacy FitLife revenue for the three months ended June 30, 2024 was $6,802, a 5% decrease compared to the previous year, driven by a 10% decline in wholesale revenue partially offset by a 7% increase in online revenue.
MRC revenue for the three months ended June 30, 2024 was $7,461, a 2% decrease compared to the previous year.
During the three months ended June 30, 2024, MusclePharm generated revenue of $2,667, of which approximately half was generated from wholesale customers and half from online sales.
Online revenue and wholesale revenue for the quarter ended June 30, 2024 were approximately 66% and 34% of total net revenue, respectively. Online revenue and wholesale revenue for the quarter ended June 30, 2023 were approximately 67% and 33% of net revenue, respectively. Although no assurances can be given, management believes that online revenue will continue to increase in subsequent periods relative to prior comparable periods given management’s focus on higher margin online sales and the acquisition of the MusclePharm assets, which was consummated in the fourth quarter of fiscal 2023.
Sales to customers in the U.S. were approximately 96% and 93% during the quarters ended June 30, 2024 and 2023, respectively, with the balance of sales to customers primarily in Canada.
Cost of Goods Sold. Cost of goods sold for the three months ended June 30, 2024 increased to $9,350 as compared to $8,795 for the three months ended June 30, 2023. This 6% increase is primarily due to an increase in revenue attributable to the acquisition of the MusclePharm assets, partially offset by lower legacy FitLife sales.
Gross Profit. Gross profit for the three months ended June 30, 2024 increased to $7,580 as compared to $5,965 for the three months ended June 30, 2023. The increase in gross profit is principally attributable to higher MRC gross profit as well as incremental gross profit from MusclePharm.
Gross Margin. Gross margin for the three months ended June 30, 2024 increased to 44.8% from 40.4% for the comparable prior period. The increase in gross margin is primarily attributable to higher margins from MRC as well as the amortization of the fair value step-up to MRC inventory acquired in the first quarter of 2023. Excluding the $213 impact of the step-up amortization, gross margin would have been 41.9% during the quarter ended June 30, 2023.
Advertising and marketing. Advertising and marketing expense for the three months ended June 30, 2024 decreased to $1,326 as compared to $1,457 for the same period of the prior year. The 9% decrease is the result of targeted efforts to rationalize the Company’s advertising spend on less effective advertising campaigns.
SG&A. SG&A expense for the three months ended June 30, 2024 increased to $2,528 as compared to $1,786 for the three months ended June 30, 2023. The increase was due to increased product testing costs required by Amazon, as well as increased professional fees and headcount additions made subsequent to the acquisition of the MusclePharm assets.
Merger and acquisition related. Merger and acquisition related expense decreased to $24 during the quarter ended June 30, 2024 compared to $115 for the same period of 2023, driven primarily by transaction costs related to the MRC acquisition in the second quarter of 2023.
Net Income. We generated net income of $2,628 for the three months ended June 30, 2024 as compared to net income of $1,964 for the three months ended June 30, 2023. The increase in net income for the three months ended June 30, 2024 compared to the same period in 2023 was primarily attributable to incremental revenue and gross profit from MusclePharm, higher gross profit from MRC, as well as reduction in advertising and marketing and acquisition-related expense.
Comparison of the six months ended June 30, 2024 to the six months ended June 30, 2023
|
Six months ended |
||||||||||||||||
|
June 30, 2024 |
June 30, 2023 |
Change ($) |
Change (%) |
|||||||||||||
|
(Unaudited) |
||||||||||||||||
|
Revenue |
$ | 33,479 | $ | 25,498 | $ | 7,981 | 31 | % | ||||||||
|
Cost of goods sold |
18,612 | 15,125 | 3,487 | 23 | % | |||||||||||
|
Gross profit |
14,867 | 10,373 | 4,494 | 43 | % | |||||||||||
|
Gross margin |
44.4 | % | 40.7 | % |
n/m |
3.7 | % | |||||||||
|
Advertising and marketing |
2,554 | 2,084 | 470 | 23 | % | |||||||||||
|
Selling, general and administrative (“SG&A”) |
5,036 | 3,502 | 1,534 | 44 | % | |||||||||||
|
Merger and acquisition related |
158 | 1,487 | (1,329 | ) | (89 | )% | ||||||||||
|
Depreciation and amortization |
63 | 42 | 21 | 50 | % | |||||||||||
|
Total operating expense |
7,811 | 7,115 | 696 | 10 | % | |||||||||||
|
Operating income |
7,056 | 3,258 | 3,798 | 117 | % | |||||||||||
|
Other expense, net |
732 | 82 | 650 | 793 | % | |||||||||||
|
Provision for income tax |
1,536 | 1,056 | 480 | 45 | % | |||||||||||
|
Net income |
$ | 4,788 | $ | 2,120 | $ | 2,668 | 126 | % | ||||||||
Revenue. Revenue for the six months ended June 30, 2024 increased 31% to $33,479 as compared to $25,498 for the six months ended June 30, 2023. The increase in revenue for the six months ended June 30, 2024 compared to the prior period is due to the acquisition of MRC and the MusclePharm assets, partially offset by a decline in legacy FitLife revenue. MRC was acquired February 28, 2023, and as such only four months of MRC revenue were included in the Company’s financial statements for the six months ended June 30, 2023. MusclePharm was acquired on October 10, 2023.
Legacy FitLife revenue for the six months ended June 30, 2024 was $13,763, a 10% decrease compared to the previous year, driven by a 16% decline in wholesale revenue partially offset by a 4% increase in online revenue.
MRC revenue for the six months ended June 30, 2024 was $14,954. MRC revenue for the period from February 28, 2023 to June 30, 2023 was $10,266.
During the six months ended June 30, 2024, MusclePharm generated revenue of $4,762, of which approximately half was generated from wholesale customers and half from online sales.
Online revenue and wholesale revenue for the six months ended June 30, 2024 were approximately 66% and 34% of total net revenue, respectively. Online revenue and wholesale revenue for the six months ended June 30, 2023 were approximately 59% and 41% of net revenue, respectively. Although no assurances can be given, management believes that online revenue will continue to increase in subsequent periods relative to prior comparable periods given management’s focus on higher margin online sales and the acquisitions of the MusclePharm assets, which was consummated in the fourth quarter of fiscal 2023.
Sales to customers in the U.S. were approximately 96% and 95% during the six months ended June 30, 2024 and 2023, respectively, with the balance of sales to customers primarily in Canada.
Cost of Goods Sold. Cost of goods sold for the six months ended June 30, 2024 increased to $18,612 as compared to $15,125 for the six months ended June 30, 2023. This 23% increase is due to an increase in revenue attributable to the acquisitions of MRC and the MusclePharm assets.
Gross Profit. Gross profit for the six months ended June 30, 2024 increased to $14,867 as compared to $10,373 for the six months ended June 30, 2023. The increase in gross profit is principally attributable to higher MRC gross profit as well as incremental gross profit from MusclePharm.
Gross Margin. Gross margin for the six months ended June 30, 2024 increased to 44.4% from 40.7% for the comparable prior period. The increase in gross margin is primarily attributable to higher margins from MRC as well as the amortization of the fair value step-up to MRC inventory acquired in the first quarter of 2023. Excluding the $323 impact of the step-up amortization, gross margin would have been 41.9% during the six months ended June 30, 2023.
Advertising and marketing. Advertising and marketing expense for the six months ended June 30, 2024 increased to $2,554 as compared to $2,084 for the same period of the prior year. The 23% increase is primarily due to the full-period impact of MRC advertising and marketing as well as incremental advertising and marketing expense attributable to the acquisition of the MusclePharm assets.
SG&A. SG&A expense for the six months ended June 30, 2024 increased to $5,036 as compared to $3,502 for the six months ended June 30, 2023. The increase was due to the full-period impact of MRC SG&A as well as incremental SG&A attributable to the acquisition of MusclePharm assets, increased product testing costs required by Amazon and increased professional fees.
Merger and acquisition related. Merger and acquisition related expense decreased to $158 during the six months ended June 30, 2024 compared to $1,487 for the same period of 2023, driven primarily by transaction costs related to the MRC acquisition in the second quarter of 2023.
Net Income. We generated net income of $4,788 for the six months ended June 30, 2024 as compared to net income of $2,120 for the six months ended June 30, 2023. The increase in net income for the six months ended June 30, 2024 compared to the same period in 2023 was primarily attributable to higher revenue and gross profit for MRC and a reduction in acquisition-related expense due to the MRC acquisition that closed during the first three months of 2023, partially offset by incremental SG&A expense.
Supplemental Discussion of Performance of Acquired Brands
Management frequently receives questions from investors regarding the performance of brands subsequent to their acquisition by the Company. In an effort to be responsive to these questions, the Company is providing additional disclosure herein. Management intends to provide this level of disclosure for no more than two years following a transaction, after which the performance of acquired brands will be reported as part of legacy FitLife results.
One of the primary metrics used by management to evaluate the performance of the Company’s brands is contribution, a non-GAAP financial measure which management defines as gross profit less advertising and marketing expenditures. Other companies may also report contribution as a performance metric, but their definition or calculation of contribution may differ from the Company’s. Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expenditures associated with the same brand or brands. With limited exceptions, other operating expenses incurred by the Company are generally not allocable to a specific brand or collection of brands.
Other than for MusclePharm, the numbers in the contribution tables presented below represent the performance of a collection of brands. Legacy FitLife consists of nine brands and MRC consists of three brands. These collections of brands do not meet the definition of operating segments and are not managed as such.
|
Legacy FitLife |
||||||||||||||||||||
| (Unaudited) |
2023 |
2024 |
||||||||||||||||||
|
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
||||||||||||||||
|
Wholesale revenue |
4,715 | 4,361 | 4,011 | 4,506 | 4,224 | |||||||||||||||
|
Online revenue |
2,418 | 2,339 | 2,134 | 2,455 | 2,578 | |||||||||||||||
|
Total revenue |
7,133 | 6,700 | 6,145 | 6,961 | 6,802 | |||||||||||||||
|
Gross profit |
2,999 | 2,490 | 2,480 | 2,928 | 3,006 | |||||||||||||||
|
Gross margin |
42.0 | % | 37.2 | % | 40.4 | % | 42.1 | % | 44.2 | % | ||||||||||
|
Advertising and marketing |
63 | 79 | 71 | 80 | 94 | |||||||||||||||
|
Contribution |
2,936 | 2,411 | 2,409 | 2,848 | 2,912 | |||||||||||||||
|
Contribution as a % of revenue |
41.2 | % | 36.0 | % | 39.2 | % | 40.9 | % | 42.8 | % | ||||||||||
For the second quarter of 2024, legacy FitLife revenue declined 5% compared to the same period last year, driven by a 10% decline in wholesale revenue partially offset by 7% increase in online revenue.
Despite the revenue decline, gross profit for legacy FitLife increased slightly and contribution decreased slightly. Gross margin increased from 42.0% during the second quarter of 2023 to 44.2% during the second quarter of 2024. Contribution as a percentage of revenue increased from 41.2% to 42.8% over the same time period.
The Company’s wholesale revenue continues to be challenged by declining customer counts in the brick-and-mortar stores of our wholesale partners. However, at least some of the customers choosing to no longer shop in brick-and-mortar locations continue to purchase legacy FitLife products online, and when a customer buys online the Company earns substantially higher gross profit and contribution.
More specifically, on a year-over-year basis during the second quarter of 2024, wholesale revenue for legacy FitLife declined by $491 and online revenue increased by $160, yet gross profit and contribution were approximately unchanged.
|
Mimi's Rock (MRC) |
||||||||||||||||||||
| (Unaudited) | 2023 | 2024 | ||||||||||||||||||
| Q2 | Q3 | Q4 | Q1 | Q2 | ||||||||||||||||
|
Wholesale revenue |
137 | 85 | 91 | 94 | 90 | |||||||||||||||
|
Online revenue |
7,490 | 7,117 | 6,811 | 7,399 | 7,371 | |||||||||||||||
|
Total revenue |
7,627 | 7,202 | 6,902 | 7,493 | 7,461 | |||||||||||||||
|
Gross profit |
2,966 | 3,206 | 2,790 | 3,520 | 3,597 | |||||||||||||||
|
Gross margin |
38.9 | % | 44.5 | % | 40.4 | % | 47.0 | % | 48.2 | % | ||||||||||
|
Advertising and marketing |
1,394 | 1,196 | 846 | 1,062 | 1,071 | |||||||||||||||
|
Contribution |
1,572 | 2,010 | 1,944 | 2,458 | 2,526 | |||||||||||||||
|
Contribution as a % of revenue |
20.6 | % | 27.9 | % | 28.2 | % | 32.8 | % | 33.9 | % | ||||||||||
For the second quarter of 2024, MRC revenue declined 2% compared to the same period in 2023. Over the same time period, gross profit increased 21% and contribution increased 61%.
For the second quarter of 2024, gross margin increased to 48.2% from 38.9% last year. Excluding the impact of the inventory step-up resulting from the acquisition of MRC, gross margin during the quarter ended June 30, 2023 would have been 41.7%.
Revenue for the largest MRC brand—Dr. Tobias—increased 4% while revenue for the skin care brands—Maritime Naturals and All Natural Advice—declined 37% in the second quarter of 2024.
At the time of the MRC acquisition in 2023, the skin care brands were sold in a number of countries. Analysis subsequent to the acquisition determined that—in almost all countries other than Canada and the US—the products were being sold at levels resulting in negative contribution. Even worse, in many of those countries, the products were being sold at negative gross margins.
To optimize performance of the skin care brands, management exited a number of countries and raised prices in other countries. As a result of these changes, a substantial amount of unprofitable revenue was eliminated.
The substantial year-over-year increase in gross profit for the MRC brands is primarily the result of this optimization of the skin care brands as well as beneficial product mix within the Dr. Tobias brand. The substantial year-over-year increase in contribution for the MRC brands is a function of the optimization of the skin care brands, beneficial product mix within the Dr. Tobias brand, as well as the optimization of advertising spend across all MRC brands.
| MusclePharm | ||||||||||||||||||||
| (Unaudited) |
2023 |
2024 |
||||||||||||||||||
|
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
||||||||||||||||
|
Wholesale revenue |
- | - | 180 | 1,117 | 1,388 | |||||||||||||||
|
Online revenue |
- | - | 73 | 978 | 1,279 | |||||||||||||||
|
Total revenue |
- | - | 253 | 2,095 | 2,667 | |||||||||||||||
|
Gross profit |
- | - | 93 | 839 | 977 | |||||||||||||||
|
Gross margin |
- | - | 36.8 | % | 40.0 | % | 36.6 | % | ||||||||||||
|
Advertising and marketing |
- | - | - | 86 | 161 | |||||||||||||||
|
Contribution |
- | - | 93 | 753 | 816 | |||||||||||||||
|
Contribution as a % of revenue |
- | - | 36.8 | % | 35.9 | % | 30.6 | % | ||||||||||||
MusclePharm revenue increased 27% sequentially from the first quarter of 2024 to the second quarter of 2024, with wholesale revenue increasing 24% and online revenue increasing 31%.
In an effort to drive revenue growth, the Company is making targeted investments in advertising and promotion in both the wholesale and online channels. As a result of these investments, gross margin and contribution margin declined as a percent of revenue, although total gross profit and contribution in dollar terms increased sequentially.
In addition, the Company is exploring additional new product launches and continues to have productive discussions with a number of potential new wholesale partners.
|
FitLife Consolidated |
||||||||||||||||||||
| (Unaudited) |
2023 |
2024 |
||||||||||||||||||
|
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
||||||||||||||||
|
Wholesale revenue |
4,852 | 4,446 | 4,282 | 5,717 | 5,702 | |||||||||||||||
|
Online revenue |
9,908 | 9,456 | 9,018 | 10,832 | 11,228 | |||||||||||||||
|
Total revenue |
14,760 | 13,902 | 13,300 | 16,549 | 16,930 | |||||||||||||||
|
Gross profit |
5,965 | 5,696 | 5,363 | 7,287 | 7,580 | |||||||||||||||
|
Gross margin |
40.4 | % | 41.0 | % | 40.3 | % | 44.0 | % | 44.8 | % | ||||||||||
|
Advertising and marketing |
1,457 | 1,275 | 917 | 1,228 | 1,326 | |||||||||||||||
|
Contribution |
4,508 | 4,421 | 4,446 | 6,059 | 6,254 | |||||||||||||||
|
Contribution as a % of revenue |
30.5 | % | 31.8 | % | 33.4 | % | 36.6 | % | 36.9 | % | ||||||||||
For the Company overall, revenue increased 15%, gross profit increased 27%, and contribution increased 39% compared to the second quarter of 2023.
Gross margin increased to 44.8% compared to 40.4% during the second quarter of last year, or 41.9% excluding the impact of the inventory step-up resulting from the acquisition of MRC.
Contribution as a percentage of revenue increased to 36.9% compared to 30.5% during the second quarter of last year, or 32.0% excluding the impact of the inventory step-up resulting from the acquisition of MRC.
Non-GAAP Measures
The financial presentation below contains certain financial measures not in accordance with GAAP, defined by the SEC as “non-GAAP financial measures”, including non-GAAP earnings before interest, taxes, depreciation, and amortization (“EBITDA”) and adjusted non-GAAP EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in this Quarterly Report in accordance with GAAP.
As presented below, non-GAAP EBITDA excludes interest, foreign exchange gains and losses, income taxes, and depreciation and amortization. Adjusted non-GAAP EBITDA excludes, in addition to interest, taxes, depreciation and amortization, stock-based compensation, merger and acquisition related expense and non-recurring expense. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company’s financial results with the Company’s historical financial results and is an important measure of the Company’s comparative financial performance.
|
For the three months ended June 30, |
For the six months ended June 30, |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
(Unaudited) |
(Unaudited) |
(Unaudited) |
(Unaudited) |
|||||||||||||
|
Net income |
$ | 2,628 | $ | 1,964 | $ | 4,788 | $ | 2,120 | ||||||||
|
Interest expense |
345 | 251 | 759 | 349 | ||||||||||||
|
Interest income |
(17 | ) | (66 | ) | (22 | ) | (150 | ) | ||||||||
|
Foreign exchange (gain) loss |
(10 | ) | (200 | ) | (5 | ) | (117 | ) | ||||||||
|
Provision for income taxes |
729 | 635 | 1,536 | 1,056 | ||||||||||||
|
Depreciation and amortization |
27 | 23 | 63 | 42 | ||||||||||||
|
EBITDA |
3,702 | 2,607 | 7,119 | 3,300 | ||||||||||||
|
Non-cash and non-recurring adjustments |
||||||||||||||||
|
Stock-based compensation |
101 | 31 | 203 | 74 | ||||||||||||
|
Merger and acquisition related |
24 | 115 | 158 | 1,487 | ||||||||||||
|
Amortization of inventory step-up |
- | 213 | - | 323 | ||||||||||||
|
Non-recurring loss on foreign currency forward contract |
- | - | - | 112 | ||||||||||||
|
Adjusted EBITDA |
$ | 3,827 | $ | 2,966 | $ | 7,480 | $ | 5,296 | ||||||||
Liquidity and Capital Resources
As of June 30, 2024, the Company had positive working capital of $4,711, compared to $4,356 at December 31, 2023. Our principal sources of liquidity at June 30, 2024 consisted of $3,735 of cash and $2,498 of accounts receivable. The slight increase in working capital is principally attributable to positive operating cash flows during the six months ended June 30, 2024, partially offset by a voluntary paydown of $2,500 on the Term Loans as well as the two scheduled amortization payments totaling $2,250.
On September 24, 2019, the Company entered into a line of credit agreement with Mutual of Omaha Bank (the “Lender”), subsequently acquired by CIT Bank N.A., then acquired by First Citizens Bank & Trust Company, providing the Company with a $2.5 million revolving line of credit (the “Line of Credit”). The Line of Credit allows the Company to request advances thereunder and to use the proceeds of such advances for working capital purposes until the maturity date, or unless renewed at maturity upon approval by the Company’s Board and the Lender. The Line of Credit is secured by all assets of the Company.
Advances drawn under the Line of Credit bear interest at an annual rate of the one-month SOFR rate plus 2.75%, and each advance will be payable on the maturity date with the interest on outstanding advances payable monthly. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to the maturity date, without premium or penalty. On September 20, 2022, the Company and the Lender amended the Line of Credit Agreement to extend the maturity date to December 23, 2022. On December 19, 2022, the Company and the Lender amended the Line of Credit agreement to increase the Line of Credit to $3.5 million and extend the maturity date to December 23, 2023.
On February 23, 2023, the Company and the Lender amended the Line of Credit Agreement (the “Credit Agreement”) providing the Company with a term loan for the principal amount of $12.5 million (“Term Loan A”). All other terms of the Credit Agreement remain unchanged. All of the proceeds from Term Loan A were used for the acquisition of MRC.
On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with the Lender, amending and restating the Credit Agreement between the Company and the Lender. Pursuant to the Amended Credit Agreement, the Lender provided the Company with an additional term loan (“Term Loan B”, and together with Term Loan A, the “Term Loans”) for the principal amount of $10,000 and extended the Line of Credit of $3.5 million to December 15, 2024. The Company used the proceeds from Term Loan B to fund the acquisition of the MusclePharm assets.
The Term Loans accrue interest at an annual rate of the one-month SOFR rate plus 2.75%, and principal plus accrued interest will be payable quarterly beginning June 10, 2023 in amounts sufficient to fully amortize the Term Loans through February 28, 2028 in the case of Term Loan A and through October 10, 2028 in the case of Term Loan B. The Company may prepay amounts borrowed under the Term Loans, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to the Lender at least one business day prior to the proposed prepayment.
The Amended Credit Agreement contains customary events of default (each an “Event of Default”), which upon the occurrence of an Event of Default, as defined in the Amended Credit Agreement, among other things, interest will accrue at the applicable rate plus 2% per annum, and the Lender may declare all obligations, with interest thereon, immediately due and payable. The Amended Credit Agreement further contains customary representations and warranties of the Company; customary indemnification provisions whereby the Company will indemnify Lender for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of the Company, and certain other matters; and customary affirmative and negative covenants, including covenants to maintain a Fixed Charge Coverage Ratio (as defined in the Amended Credit Agreement) of not less than 1.25 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending December 31, 2023, a Funded Debt to EBITDA Ratio (as defined in the Amended Credit Agreement) of not more than 2.50 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending March 31, 2024, and to the extent the Term Loans still have a balance as of June 30, 2025 and a Cash Flow Leverage threshold (as defined in the Amended Credit Agreement) of at least 1.15 is not met, the Company will be required to make a prepayment on the Term Loans equal to 50% of the Excess Cash Flow (as defined in the Amended Credit Agreement). The Company was in compliance with all covenants as of June 30, 2024.
As of June 30, 2024, the borrowings outstanding on the Term Loans and the Line of Credit were $15,375 and $0, respectively.
The Company has historically financed its operations primarily through cash flow from operations and equity and debt financings. The Company currently anticipates that cash derived from operations and existing cash reserves, along with available borrowings under the Line of Credit, will be sufficient to provide for the Company’s liquidity for the next twelve months.
The Company is dependent on cash flow from operations and amounts available under the Line of Credit to satisfy its working capital requirements. No assurances can be given that cash flow from operations and/or the Line of Credit will be sufficient to provide for the Company’s liquidity for the next twelve months. Should the Company be unable to generate sufficient revenue in the future to achieve positive cash flow from operations, and/or should capital be unavailable under the terms of the Line of Credit, additional working capital will be required. Management currently has no intention to raise additional working capital through the sale of equity or debt securities and believes that the cash flow from operations and available borrowings under the Line of Credit will provide sufficient capital necessary to operate the business over the next twelve months. In the event the Company fails to achieve positive cash flow from operations, additional capital is unavailable under the terms of the Line of Credit, and management is otherwise unable to secure additional working capital through the issuance of equity or debt securities, the Company’s business would be materially and adversely harmed.
Cash Provided by Operating Activities. Cash provided by operating activities for the six months ended June 30, 2024 was $6,606, as compared to cash provided by operations of $1,794 for the six months ended June 30, 2023. The increase in cash provided by operating activities was driven primarily by the higher net income achieved in the first six months of 2024 driven by the acquisitions of MRC and the MusclePharm assets, as well as the payment of the transaction-related costs and other payables and expenses that were accrued at MRC at the time of the acquisition during the same period of 2023.
Cash Used in Investing Activities. Cash used in investing activities for the six months ended June 30, 2024 and 2023 was $10 and $17,153, respectively. The Company used $10 and $54 for purchases of property and equipment in the six months ended June 30, 2024 and 2023, respectively. During the six-month period ended June 30, 2023, the Company paid $17,099 to acquire MRC.
Cash Provided by (Used in) Financing Activities. Cash used in financing activities for the six months ended June 30, 2024 was $4,750 compared to cash provided by financing activities of $11,875 during the three months ended June 30, 2023.
Critical Accounting Policies and Estimates
Our discussion and analysis of financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expense, and related disclosure of contingent assets and liabilities. We evaluate, on an on-going basis, our estimates and judgments, including those related to the useful life of the assets. We base our estimates on historical experience and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results that we report in our condensed consolidated financial statements. The SEC considers an entity’s most critical accounting policies to be those policies that are both most important to the portrayal of a company’s financial condition and results of operations and those that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain at the time of estimation. For a more detailed discussion of the accounting policies of the Company, see Note 3 of the Notes to the Condensed Consolidated Financial Statements included in this Quarterly Report, “Summary of Significant Accounting Policies”.
We believe the following critical accounting policies, among others, require significant judgments and estimates used in the preparation of our consolidated financial statements.
Use of Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.
Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.
Goodwill
In accordance with FASB ASC 350, Intangibles-Goodwill and Other, we review goodwill and indefinite lived intangible assets for impairment at least annually or whenever events or circumstances indicate a potential impairment. Our impairment testing is performed annually at December 31 (our fiscal year end). Impairment of goodwill and indefinite lived intangible assets is determined by comparing the fair value of our reporting units to the carrying value of the underlying net assets in the reporting units. If the fair value of a reporting unit is determined to be less than the carrying value of its net assets, goodwill is deemed impaired and an impairment loss is recognized to the extent that the carrying value of goodwill exceeds the difference between the fair value of the reporting unit and the fair value of its other assets and liabilities.
Management concluded that a triggering event did not occur during the three months ended June 30, 2024. We will continue to review for impairment indicators as necessary in future periods.
Revenue Recognition
The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.
The Company accounts for revenue in accordance with FASB ASC 606. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer.
All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.
The Company’s products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording platform fees paid to Amazon as an expense or as a reduction of revenue. The Company records platform fees paid to Amazon for distribution of Company products to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees for Amazon are recorded in selling, general and administrative expenses in the condensed consolidated statements of income and comprehensive income.
The Company disaggregates revenue into geographical regions and distribution channels. The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.
Online revenue during the quarter ended June 30, 2024 was approximately 66% of net revenue, compared to 34% for wholesale channels for the same period. Online revenue during the quarter ended June 30, 2023 was 67% of net revenue compared to 33% for wholesale channels during the same period in 2022.
Online revenue during the six months ended June 30, 2024 was approximately 66% of net revenue, compared to 34% for wholesale channels for the same period. Online revenue during the six months ended June 30, 2023 was 59% of net revenue compared to 41% for wholesale channels during the same period in 2023.
Sales to customers in the U.S. were approximately 96% and 93% during the three months ended June 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada.
Sales to customers in the U.S. were approximately 96% and 95% during the six months ended June 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada.
Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.
For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the FDA.
A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.
Recent Accounting Pronouncements
See Note 3 of the Condensed Consolidated Financial Statements included in this Quarterly Report for a description of recent accounting pronouncements believed by management to have a material impact on our present or future financial statements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our business is conducted principally in the U.S. However, due to the MRC acquisition in 2023, the Company now has more exposure to fluctuations in foreign currencies. As a result, our financial results may be materially affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets.
Foreign Currency
In January 2023, the Company entered into a foreign currency hedging transaction to mitigate the risk of adverse changes in the USD/CAD exchange rate with respect to the pending acquisition of MRC. The Company entered into a forward contract to purchase CAD $25.0 million, as the Company anticipated providing additional working capital funding beyond the CAD $23.2 million purchase price for MRC. As the geographical scope of our business broadens, we may engage in additional foreign currency hedging transactions in the future.
Interest Rates
Our exposure to risk for changes in interest rates relates primarily to borrowings under the Amended Credit Agreement (which includes the Term Loans as well as our Line of Credit), and our investments in short-term financial instruments. As of June 30, 2024, the Company had $15,375 outstanding on the Term Loans and $0 under its Line of Credit.
Investments of our cash balances in both fixed-rate and floating-rate interest-earning instruments carry some interest rate risk. The fair value of fixed-rate securities may fall due to a rise in interest rates, while floating-rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income will vary due to changes in interest rates and we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.
ITEM 4. CONTROLS AND PROCEDURES
|
a. |
Evaluation of disclosure controls and procedures. |
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of June 30, 2024 was completed. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer believe that our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including to ensure that information required to be disclosed by the Company is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
|
b. |
Changes in Internal Control Over Financial Reporting |
There were no additional changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
|
c. |
Inherent Limitations on the Effectiveness of Controls |
Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ directors or officers in their capacities as such, in which an adverse decision could have a material adverse effect.
ITEM 1A. RISK FACTORS
Our results of operations and financial condition are subject to numerous risks and uncertainties described in our comprehensive Annual Report on Form 10-K for our fiscal year ended December 31, 2023, filed with the SEC on March 29, 2024. Management is not aware of any material changes to the risk factors discussed in Part 1, Item 1A, of the Annual Report on Form 10-K for the year ended December 31, 2023. You should carefully consider these risk factors in conjunction with the other information contained in this Quarterly Report. Should any of these risks materialize, our business, financial condition and future prospects could be negatively impacted.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
There were no defaults upon senior securities during the three-month period ended June 30, 2024.
ITEM 5. OTHER INFORMATION
In the three months ended June 30, 2024, directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
ITEM 6. EXHIBITS
|
31.1 |
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act. |
|
|
31.2 |
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act. |
|
|
32.1 |
Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act. |
|
|
32.2 |
Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act. |
|
|
101.INS |
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
|
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL Document and included in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Registrant |
FitLife Brands, Inc. |
||
|
Date: August 14, 2024 |
By: |
/s/ Dayton Judd |
|
|
Dayton Judd |
|||
|
Chief Executive Officer and Chair (Principal Executive Officer) |
|||
|
Registrant |
FitLife Brands, Inc. |
||
|
Date: August 14, 2024 |
By: |
/s/ Jakob York |
|
|
Jakob York |
|||
|
Chief Financial Officer (Principal Financial Officer) |
|||